Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in Polymyalgia Rheumatica (SAPHYR)
NCT03600818Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Oct 2018
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of sarilumab in polymyalgia rheumatica (PMR), sponsored by Sanofi. Started Oct 2018; status: terminated.
02
Drugs
sarilumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT03600818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600818.